Regenerative Medicine

BioRestorative (BRTX) appointed Crystal Romano as Head of Global Commercial Operations on October 22, 2025. Romano brings 19 years of experience in medical aesthetics and regenerative industries, including a role at Cartessa where she helped commercialize 11 new products in under two years. The appointment aims to accelerate the commercialization of BioRestorative’s cell-based platforms, including BRTX-100, currently in Phase 2 trials, and unlock near-term revenue opportunities. Romano’s expertise is seen as a positive signal due to her experience in regulatory and commercial landscapes.

Kelyniam Global’s CFO, Terrance Kurtenbach, will present at the Life Sciences Virtual Investor Forum on September 18, 2025, at 10:00 AM EDT. The forum allows investors to learn about Kelyniam’s growth strategy and innovative custom cranial implants leveraging CAD/CAM technology and advanced medical-grade polymers. Management will be available for one-on-one meetings. Kelyniam focuses on personalized solutions and is expanding into regenerative medicine with licensed products.

Adia Nutrition (OTCQB: ADIA) launches its second national TV campaign, promoting Adia Med’s stem cell therapies for sports injuries, orthopedic issues, chronic pain, and wound repair at its Winter Park, Florida clinic. Targeting the $25 billion wound care market, Adia Med aims to make regenerative treatments more accessible domestically. The company is in-network with UnitedHealthcare and Aetna, awaiting TRICARE approval. Florida’s SB1768, recognizing stem cell therapy’s benefits, boosts this initiative. The therapies provide alternatives to overseas medical tourism.

Creative Medical Technology (CELZ) secured USPTO patent allowance through 2040 for its ImmCelz™ therapy targeting heart failure and post-heart attack damage. The treatment, delivered via minimally invasive outpatient procedure, addresses a potential US patient population exceeding 11 million. While this significantly broadens the company’s regenerative medicine IP portfolio, the therapy remains in development and lacks FDA approval or current revenue.

Hemostemix’s ACP-01 therapy, a novel cellular treatment for heart failure, has been detailed in a peer-reviewed paper. Targeting non-ischemic dilated cardiomyopathy, ACP-01 utilizes autologous cells to combat inflammation, fibrosis, and improve blood flow. Earlier studies showed significant improvement in cardiac function, with LVEF increases up to 47.1% in DCM patients. The therapy is now available in Florida under new legislation, offering a promising option for patients with limited alternatives.